HopeStage
Back to overview

ADHD studies

Topics
More filters

Some studies do not list a clear city. Always confirm the location with the study team.

Some visits may still be in person. Participation depends on the study’s location and eligibility requirements.

ADHD

Attention-deficit/hyperactivity disorder (ADHD) involves persistent difficulties with attention, impulsivity or restlessness that can affect everyday life.

1811studies shown
Showing 169-180 of 1,811
Drug study icon
WithdrawnNCT03536390

Safety study of Safety and Efficacy of Methylphenidate HCl ERCT in ADHD

What is this study about?

This study evaluates the safety and effectiveness of Methylphenidate Hydrochloride (HCl) Extended Release Chewable Tablet (ERCT) for people with ADHD.

This study was withdrawn before enrollment.

Location not clearly listed
ADHDMedication studyAges 48–69 months
Countries
Sponsor
Pfizer
Drug study icon
WithdrawnNCT03580005

Safety study of Safety and Efficacy of Quillichew ERCT in ADHD

Official study title

A Phase 4, Double-blind, Randomized, Parallel Group, Placebo-controlled Study Of The Efficacy And Safety Of Quillichew (Methylphenidate Hydrochloride (Hcl)) Extended Release Chewable Tablets (Erct) In 4-5 Year Old Children With Attention Deficit Hyperactivity Disorder (Adhd)

This study was withdrawn before enrollment.

Location not clearly listed
ADHDMedication studyAges 4–5
Countries
Sponsor
Pfizer
Behavioral study icon
CompletedNCT06604845

A Comparison of Group Cognitive Behavioural Therapy (CBT) and Structured Activity Group for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

Official study title

A Single-blind Randomised Controlled Trial of Group Cognitive Behavioural Therapy (CBT) Versus Activity Group Control Condition for Adults With Attention Deficit Hyperactivity Disorder (ADHD)

This study has finished and is no longer accepting participants.

In Gothenburg
ADHDBehavioural studyAges 18+
Countries
Sweden
Sponsor
Vastra Gotaland Region
Drug study icon
CompletedNCT01933880

A Long Term Post-Marketing Study on the EffIcacy and Safety of Osmotic Release Oral System (OROS) Methylphenidate on the Cognitive Functions of Attention Deficit Hyperactivity Disorder (ADHD) Participants

Official study title

An Open, Self-Controlled, Prospective Study of Concerta on Cognitive Functions, Efficacy and Tolerance in the Pediatric Patients With Attention Deficit Hyperactivity Disorder (ADHD)

This study has finished and is no longer accepting participants.

Multiple locations, including Beijing
ADHDMedication studyAges 7–12
Countries
China
Sponsor
Xian-Janssen Pharmaceutical Ltd.
Drug study icon
CompletedNCT00700427

A Long Term Study of a Medication for Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

Official study title

Maintenance of Response After Open-Label Treatment With Atomoxetine Hydrochloride in Adult Outpatients With Attention-Deficit/Hyperactivity Disorder (ADHD): A Placebo-Controlled, Randomized Withdrawal Study

This study has finished and is no longer accepting participants.

Multiple locations, including Vienna
ADHDMedication studyAges 18–50
Countries
France, United Kingdom, Switzerland, + 9 others
Sponsor
Eli Lilly and Company
Other study type icon
CompletedNCT03233867

A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations

Official study title

A Non-interventional Study to Identify Children and Adolescents (Ages 6-17 Years) With Attention Deficit Hyperactivity Disorder and With or Without Copy Number Variants in Specific Genes Involved in Glutamatergic Signaling and Neuronal Connectivity

This study has finished and is no longer accepting participants.

In Wayne
ADHDObservational studyAges 6–17
Countries
United States
Sponsor
Aevi Genomic Medicine, LLC, a Cerecor company
Drug study icon
CompletedNCT01886469

A Phase II, Adaptive study Design Examining the Pharmacokinetic and Pharmacodynamic Effects of Modified Release Amphetamine (HLD100, Formulations B, C and E)) in Adolescents and Children With Attention-Deficit Hyperactivity Disorder (ADHD)

Official study title

A Phase II, Two-Stage, Open-Label, Single-Treatment, Adaptive Trial Design Examining the Pharmacokinetic and Pharmacodynamic Effects of up to Three Separate HLD100 Modified Release Formulations of Dextroamphetamine Sulfate in Adolescent (Stage 1) and Pediatric (Stage 2) Patients With Attention-Deficit Hyperactivity Disorder.

This study has finished and is no longer accepting participants.

In Saskatoon
ADHDMedication studyAges 6–17
Countries
Canada
Sponsor
Ironshore Pharmaceuticals and Development, Inc

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.